World Health Organization Guidelines for the Treatment of Multidrug-Resistant Tuberculosis
Letter to Dr. Tedros Adhanom Ghebreyesus, Director-General, WHO, and Dr. Tereza Kasaeva, Global TB Program Director.
Higher Funding for TB Research Signals Hope, but Governments Must Dramatically Increase Spending to End TB
Global funding for tuberculosis (TB) research reached a previously unreported high of $726 million in 2016, according to a report released today by Treatment Action Group (TAG) and the United Nations–hosted Stop TB Partnership.
Tools to Help Support Activists in Engaging National Policy Makers on TB
The United Nations High Level Meeting (HLM) on TB is rapidly approaching. The U.N. HLM on TB will take place on September 26, 2018 during the second day of general debate of the General Assembly at its seventy-third session…
No Time to Lose: G20 Leaders Must Fund R&D to End TB
In advance of World TB Day, Treatment Action Group (TAG), Health GAP, AIDS-Free World and Treatment Action Campaign (TAC) urge G20 member states to commit by the July 7, 2017 G20 summit to increase annual funding contributions to USD $1.17 billion for research and development (R&D) to set us on the path to end tuberculosis (TB).
LAM PEPFAR Request
February 8, 2017: TAG and partner organizations advocating for the rights of people affected by HIV and TB around the world encouraged the President’s Emergency Plan for AIDS Relief (PEPFAR) to support the immediate introduction of the LAM test in all PEPFAR-funded…
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug
Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.
TAG Responds to the Release of the World Health Organization’s 2016 Global Tuberculosis Report
TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated
Tuberculosis Research at Risk as Big Pharma Shutters Programs
Worldwide governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group.
Letter Urging AstraZeneca to Continue to Invest in TB Research
February 13, 2014 TAG, CRAG, and the TB CAB sent an open letter to AstraZeneca urging their continued investment in tuberculosis research despite the cessation of AstraZeneca’s Neglected Tropical Diseases, Tuberculosis, and Malaria Program. Read/Download the TAG, CRAG, TB CAB…
Open Letter: Appreciation for Sanofi US Committing to Lower Price of Rifapentine
This letter from CRAG (TB Community Research Advisors Group) and TAG was sent to Anne Whitaker, President, North America Pharmaceuticals of Sanofi US. It commends Sanofi for making this commitment to lower the price of rifapentine for Public Health Service…